home All News open_in_new Full Article

Novartis eleva su beneficio un 29% en el primer semestre de 2025 impulsado por tres medicamentos clave

Las ventas crecen un 12% entre enero y junio, según los resultados publicados este jueves por la compañía farmacéutica. Más información: Johnson & Johnson, GSK y Novartis lideraron las compras más grandes del primer trimestre de 2025


today 4 w. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 2747613054
Add Watch Country

arrow_drop_down